CorMedix gains hard-fought approval for combo drug that reduces risk of catheter infection during dialysis

CorMedix went through a lot to secure its FDA approval for DefenCath. There was a reorganization, a CEO change, an exit from Europe, two complete response letters and a switch of manufacturers and suppliers.